Investment Thesis
Aardvark Therapeutics is a pre-revenue pharmaceutical company with zero cash generation, operating losses of $22.5M, and sharply deteriorating net losses (down 179.7% YoY). While the balance sheet is strong with $62.4M cash and zero debt, the accelerating burn rate and absence of revenue indicate fundamental business dysfunction requiring urgent turnaround or additional capital infusion.
Strengths
- Strong cash position of $62.4M provides 3+ year runway at current burn rate
- Excellent liquidity ratios (8.06x current/quick ratio) enable operational flexibility
- Zero debt and clean balance sheet with $87M stockholders equity reduce financial distress risk
Risks
- Complete revenue collapse ($0 YoY) indicates failed commercialization or abandoned pipeline
- Net losses deteriorating severely at 179.7% YoY rate suggesting accelerating cash burn
- Operating cash outflow of $18.9M annually unsustainable long-term; cash runway finite despite adequate balance sheet
- No insider activity in 90 days suggests either restricted trading or lack of management confidence
Key Metrics to Watch
- Quarterly cash burn rate and months of cash remaining
- Path to revenue generation or clinical milestone achievements
- Operating loss trend - stabilization or further deterioration
- Capital raise activity and dilution impact on equity
Financial Metrics
Revenue
0.0
Net Income
-21.6M
EPS (Diluted)
$-0.99
Free Cash Flow
-19.0M
Total Assets
98.6M
Cash
62.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-24.8%
ROA
-21.9%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
8.06x
Quick Ratio
8.06x
Debt/Equity
0.00x
Debt/Assets
11.8%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T08:26:57.842194 |
Data as of: 2026-03-31 |
Powered by Claude AI